phrykt

Alnylam Pharmaceuticals (ALNY) cash: $1.7B

Alnylam Pharmaceuticals held $1.7B in cash and cash equivalents on Dec 31, 2025, up 71.5% from $966M a year earlier.

From Alnylam Pharmaceuticals's filings with the SEC · Read the filing · ALNY stock page

Alnylam Pharmaceuticals cash by year

$820M2021$866M2022$813M2023$966M2024$1.7B2025

#340 of 4,171 US companies by cash · See the full ranking

Year endedCashChange
Dec 31, 2025$1.7B+71%
Dec 31, 2024$966M+19%
Dec 31, 2023$813M-6%
Dec 31, 2022$866M+6%
Dec 31, 2021$820M–

Cash of similar companies

Companies in the same industry as Alnylam Pharmaceuticals, by SEC industry code, with the closest cash. Each name opens the same page for that company.

CompanyCash, latest yearYear ended
Alnylam Pharmaceuticals$1.7BDec 31, 2025
United Therapeutics$1.6BDec 31, 2025
Roivant Sciences$1.5BDec 31, 2025
Jazz Pharmaceuticals$1.4BDec 31, 2025
Viatris$1.3BDec 31, 2025
Biomarin Pharmaceutical$1.3BDec 31, 2025
Bausch Health Companies$1.3BDec 31, 2025

Questions and answers

What is Alnylam Pharmaceuticals's cash?

Alnylam Pharmaceuticals held $1.7B in cash and cash equivalents on Dec 31, 2025, up 71.5% from $966M a year earlier.

Numbers as reported in Alnylam Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology